Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated Jan 14, 2020 (7 years ago)

methylPREDNISolone Sodium Succinate For Injection

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Labeling: Incorrect Instructions: Vial label incorrectly instructs healthcare professional to reconstitute product with 16 mL rather than the correct volume of 8 mL of Bacteriostatic Water for Injection with Benzyl Alcohol.

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

methylPREDNISolone Sodium Succinate For Injection, USP, 500 mg*/vial, Rx Only, Mfd by: HIKMA FARMACEUTICA (PORTUGAL), SA; Dist by: WEST-WARD, Eatontown, NJ 07724, NDC 0143-9850-01.

Affected NDC 0143-9850-01

Compare with the code on your package — it is the most precise check available.

Drug: Methylprednisolone

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Methylprednisolone Sodium Succinate
NDC 00143-9850
500 mg/1 Injection, Powder, for Solution
Intramuscular|intravenous
Hikma Pharmaceuticals USA Inc. Rx
Recalling firm
Hikma Pharmaceuticals USA Inc.
NDC code
0143-9850-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0801-2020 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Methylprednisolone recalls

See all
Class II · Moderate risk

methylprednisolone tablets

Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

Ongoing Labeling / mix-up Greenstone Llc NDC 59762-4440-2 D-0299-2026
Class III · Low risk

Methylprednisolone Acetate Injectable Suspension

Labeling: Not Elsewhere Classified; A typographical error was observed in the NDC number on the preprinted Individual Folding Cartons (secondary packaging only). Incorrect NDC Number 70121-1573-1; Correct NDC Number 70121-1574-1.

Terminated Labeling / mix-up Amneal Pharmaceuticals of New York, LLC NDC 70121-1574-01 D-0756-2023

Other recalls by Hikma Pharmaceuticals USA Inc.

All 2020 recalls
Class II · Moderate risk

Ramipril Capsules USP

Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclohexylurea (DCU).

Ongoing Impurity / degradation Hikma Pharmaceuticals USA INC. NDC 76282-673-01 D-0831-2026
Class II · Moderate risk

Alendronate Sodium Oral Solution

This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.

Ongoing Wrong potency / content Hikma Pharmaceuticals USA INC NDC 0054-0282-59 D-0526-2026
Class II · Moderate risk

Lorazepam Injection

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

Ongoing Impurity / degradation Hikma Pharmaceuticals USA Inc. NDC 0641-6044-25 D-0551-2025
Class I · High risk

Acetaminophen Injection

Labeling: Label Mix-up: a bag of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection was found inside an overwrap labeled Acetaminophen Injection 1,000 mg per 100 mL (10 mg/mL)

Ongoing Labeling / mix-up Hikma Pharmaceuticals USA Inc. NDC 0143-9386-01 D-0635-2024